The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.
December 6th 2024
A look into how SGLT2 inhibitors, GLP-1 RAs, and nsMRAs have redefined the management of cardio-kidney-metabolic diseases.
November 26th 2024
November 16th 2024
HCPLive Endocrinology's flagship diabetes podcast, hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP
Pharmacist-Led Interventions Can Improve HbA1c in Underserved Communities
September 29th 2023A study from UCLA suggests a pharmacist-led intervention contributed to improved HbA1c in Hispanic adults with type 2 diabetes management, underlining its potential to enhance outcomes in underserved populations.
Tirzepatide Bests Semaglutide For A1c, Weight Loss in Indirect Comparison of Clinical Trial Data
September 25th 2023A network meta-analysis suggests tirzepatide may be more effective than semaglutide in reducing HbA1c and body weight in type 2 diabetes but may increase gastrointestinal adverse events, especially at higher doses.
Type 1 and Type 2 Diabetes Incidence Increased During COVID-19 Pandemic
September 21st 2023An analysis of patient data from a health system in southern California suggests both type 1 and type 2 diabetes rates rose among younger populations during the COVID-19 pandemic, affecting non-Hispanic Black and Hispanic youth most significantly.
Study Examines Prevalence, Drivers of Racial Disparities in T2D Following Gestational Diabetes
September 11th 2023An analysis of data from more than 20,000 women in the New York City A1c registry details the prevalence of and drivers behind racial/ethnic disparities in the incidence of type 2 diabetes following gestational diabetes mellitus.
Diabetes Dialogue: Making Sense of Semaglutide in Type 1 Diabetes
September 7th 2023In this episode, hosts sit down for a discussion around a recent NEJM report assessing the effects of semaglutide use in people with type 1 diabetes, including the implications of the findings and their real-world experiences with GLP-1 use in people with type 1 diabetes.
Semaglutide Could Eliminate Need for Insulin in Type 1 Diabetes
September 6th 2023A case series of 10 patients with newly diagnosed type 1 diabetes provides insight into the beneficial effects of off-label semaglutide use on insulin use, HbA1c, and fasting C-peptide levels among this patient population.
Advanced Hybrid Closed-Loop Technology Could Improve Quality of Life in Type 1 Diabetes
September 5th 2023A 1-year observational follow-up of a 3-month RCT provides insight into he benefits of advanced hybrid closed-loop system use in people with type 1 diabetes using multiple daily injections and self-monitoring of blood glucose.
Endocrine Case Report: Diarrhea and Weight Loss
September 5th 2023This endocrine case report from Brady Pregerson, MD, features a patients in his mid-70s with a history of hypothyroidism presenting with weeks of nausea, vomiting, and diarrhea without blood but with a 30-pound weight loss. Can you determine the most likely diagnosis?
Diabetes Dialogue: Addressing Health Disparities with Diabetes Technology, with Etty Vider, PharmD
August 31st 2023During this episode, hosts are joined by Etty Vider, PharmD, for a nuanced discussion surrounding leveraging diabetes technology to improve care for people with diabetes, including exploring strategies for improving the utilization of diabetes technology, the role of primary care in adoption of these technologies, and how improved uptake correlates to improved outcomes.
Biden Administration, CMS Reveal First 10 Drugs Set for Price Negotiation
August 29th 2023On August 29, 2023, the Biden Administration debuted the list of the first 10 drugs identified for price negotiation under the Inflation Reduction Act. The list, which includes agents indicated for diabetes, heart failure, GI conditions, and arthritis, accounted for more than $50 billion in spending during the evaluation period.
Diabetes Dialogue: STEP-HFpEF Reaction
August 27th 2023Less than 2 weeks after the release of their SELECT reaction podcast, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down for a special edition episode of Diabetes Dialogue to discuss STEP-HFpEF data and the implications for semaglutide 2.4 mg.